GSK 3359609

Drug Profile

GSK 3359609

Alternative Names: GSK3359609

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Inducible T-cell co-stimulator protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 30 Jun 2016 Phase-I clinical trials in Solid tumours in Canada (IV) (NCT02723955; 9198913)
  • 04 Apr 2016 GlaxoSmithKline plans a first-in-human phase I trial for Solid tumours (Combination therapy, Monotherapy, Second-line therapy or greater, Late-stage disease, Metastatic disease, Recurrent) in USA, Canada and Australia (IV) (NCT02723955)
  • 24 Mar 2016 Preclinical trials in Solid tumours in Canada (IV) (NCT02723955)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top